There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aimmune Therapeutics (AIMT) and T2 Biosystems (TTOO) with bullish sentiments.
Aimmune Therapeutics (AIMT)
In a report released today, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on Aimmune Therapeutics, with a price target of $45. The company’s shares closed yesterday at $22.29, close to its 52-week low of $20.94.
Duncan observed:
“. We reiterate our Overweight rating and 12-month price target of $45 on shares of AIMT. We recently hosted Aimmune management for investor meetings and came away with enhanced conviction about AR101 approvability and commercial prospects. Recently, Aimmune announced that the P3 ARTEMIS study in the EU met its primary endpoint (data at EAACI June 2), making it the only company to successfully complete two P3 studies in peanut allergy (PA), underscoring the “notable” efficacy of AR101 compared with other desensitization methods. The company also announced its BLA was accepted for review by the FDA, and we believe the process is now gaining traction.”
According to TipRanks.com, Duncan is a 4-star analyst with an average return of 5.8% and a 51.6% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Crinetics Pharmaceuticals Inc, and KalVista Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aimmune Therapeutics with a $57.75 average price target.
See today’s analyst top recommended stocks >>
T2 Biosystems (TTOO)
In a report released today, Jordan Abrams from Cantor Fitzgerald reiterated a Buy rating on T2 Biosystems, with a price target of $10. The company’s shares closed yesterday at $3.08, close to its 52-week low of $2.47.
Abrams observed:
“. We reiterate our Overweight rating and 12-month PT of $10 on shares of TTOO. We conducted a 25-person survey of emergency medicine physicians all familiar with T2’s technology to understand physician perspective on T2 Bacteria. On average, our polled physicians think market penetration of T2 Bacteria will grow to 11.1% and 22.2% in one and two years from now, respectively. Significantly, 72% of respondents would clinically change the way he or she treats patients with T2 Bacteria. Physicians think T2 Bacteria is clinically appropriate for 65% of all patients suspected of sepsis, translating to an addressable $313MM annual sepsis diagnostic market.”
According to TipRanks.com, Abrams is ranked #2418 out of 5181 analysts.
Currently, the analyst consensus on T2 Biosystems is a Strong Buy with an average price target of $11.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
